Dr. Mohammed N. Al Hallak
Claim this profileWayne State University/Karmanos Cancer Institute
About Mohammed N. Al Hallak
Education:
Obtained MD from Aleppo University Faculty of Medicine, Syria (1999-2005).
Master of Science in Clinical Research Design and Statistical Analysis from the University of Michigan, Ann Arbor, MI (2015-2017).
Experience:
Completed Internal Medicine Residency at the University of North Dakota School of Medicine and Health Sciences, Sanford Hospital, Fargo, ND (2008-2011).
Hematology-Oncology Fellowship followed by a Gastrointestinal Medical Oncology Fellowship at Karmanos Cancer Institute, Wayne State University, Detroit, MI (2017-2020).
Currently an Assistant Professor - Clinical, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, and House Staff Physician in Bone Marrow Transplant at Karmanos Cancer Institute, Detroit, MI (2018-Present).
Area of expertise
Pancreatic Cancer
Mohammed N. Al Hallak has run 7 trials for Pancreatic Cancer. Some of their research focus areas include:
Colorectal Cancer
Mohammed N. Al Hallak has run 4 trials for Colorectal Cancer. Some of their research focus areas include:
Affiliated Hospitals
Wayne State University/Karmanos Cancer Institute
Weisberg Cancer Treatment Center
Clinical Trials Mohammed N. Al Hallak is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting
2 awards
Phase 3
2 criteria
Atezolizumab + Chemotherapy
for Neuroendocrine Carcinoma
This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.
Recruiting
1 award
Phase 2 & 3
10 criteria
More about Mohammed N. Al Hallak
Clinical Trial Related
5 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Mohammed N. Al Hallak has experience with
- Atezolizumab
- Nivolumab
- Fluorouracil
- Ipilimumab
- Oxaliplatin
- Olaparib
Breakdown of trials Mohammed N. Al Hallak has run
Pancreatic Cancer
Colorectal Cancer
Cancer
Stomach Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mohammed N. Al Hallak specialize in?
Mohammed N. Al Hallak focuses on Pancreatic Cancer and Colorectal Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are CLDN18.2 positive.
Is Mohammed N. Al Hallak currently recruiting for clinical trials?
Yes, Mohammed N. Al Hallak is currently recruiting for 5 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Mohammed N. Al Hallak has studied deeply?
Yes, Mohammed N. Al Hallak has studied treatments such as Atezolizumab, Nivolumab, Fluorouracil.
What is the best way to schedule an appointment with Mohammed N. Al Hallak?
Apply for one of the trials that Mohammed N. Al Hallak is conducting.
What is the office address of Mohammed N. Al Hallak?
The office of Mohammed N. Al Hallak is located at: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan 48201 United States. This is the address for their practice at the Wayne State University/Karmanos Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.